Experimental vaccine combo aims to supercharge immune attack on bile duct cancer
NCT ID NCT06564623
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase study tests a personalized peptide vaccine (mBTCvax) combined with two immunotherapy drugs (durvalumab and tremelimumab) in 25 adults with advanced biliary tract cancer. The goal is to see if the combination is safe and can boost the immune system's ability to target cancer cells. Participants must have already received standard chemotherapy and have tumors with specific genetic mutations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized mutant peptide vaccine (mBTCvax) with Poly-ICLC adjuvant, durvalumab, and tremelimumab
What this could lead to
If it works, this could point toward a new treatment option that helps the immune system fight biliary tract cancer more effectively.
What could go wrong
This is a very early, small Phase 1 pilot study with only 25 participants. The combination may cause serious side effects, and it is unknown if it will improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SKCCC Johns Hopkins Medical Institution
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact